tetano
Editor, Senior Moderator
Antiviral Res. 2013 Sep 4. pii: S0166-3542(13)00243-X. doi: 10.1016/j.antiviral.2013.08.023. [Epub ahead of print]
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Burnham AJ, Baranovich T, Govorkova EA.
Source
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, USA.
Abstract
Many aspects of the biology and epidemiology of influenza B viruses are far less studied than for influenza A viruses, and one of these aspects is effectiveness and resistance to the clinically available antiviral drugs, the neuraminidase (NA) inhibitors (NAIs). Acute respiratory infections are one of the leading causes of death in children and adults, and influenza is among the few respiratory infections that can be prevented and treated by vaccination and antiviral treatment. Recent data has suggested that influenza B virus infections are of specific concern to pediatric patients because of the increased risk of severe disease. Treatment of influenza B is a challenging task for the following reasons: This review presents current knowledge of the effectiveness of NAIs for influenza B virus and antiviral resistance in clinical, surveillance, and experimental studies.
Copyright ? 2013. Published by Elsevier B.V.
KEYWORDS:
Antiviral drug resistance, Influenza B virus, Neuraminidase inhibitors, Oseltamivir, Peramivir, Zanamivir
PMID:
24013000
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24013000
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Burnham AJ, Baranovich T, Govorkova EA.
Source
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, USA.
Abstract
Many aspects of the biology and epidemiology of influenza B viruses are far less studied than for influenza A viruses, and one of these aspects is effectiveness and resistance to the clinically available antiviral drugs, the neuraminidase (NA) inhibitors (NAIs). Acute respiratory infections are one of the leading causes of death in children and adults, and influenza is among the few respiratory infections that can be prevented and treated by vaccination and antiviral treatment. Recent data has suggested that influenza B virus infections are of specific concern to pediatric patients because of the increased risk of severe disease. Treatment of influenza B is a challenging task for the following reasons: This review presents current knowledge of the effectiveness of NAIs for influenza B virus and antiviral resistance in clinical, surveillance, and experimental studies.
Copyright ? 2013. Published by Elsevier B.V.
KEYWORDS:
Antiviral drug resistance, Influenza B virus, Neuraminidase inhibitors, Oseltamivir, Peramivir, Zanamivir
PMID:
24013000
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24013000